303 related articles for article (PubMed ID: 32495916)
1. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Wang L; Peng X; Wang ZH; Cai J; Zhou FC
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
[TBL] [Abstract][Full Text] [Related]
2. Lack of tocilizumab effect on mortality in COVID19 patients.
Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
[TBL] [Abstract][Full Text] [Related]
3. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
4. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
5. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
6. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
7. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
[No Abstract] [Full Text] [Related]
9. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
10. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.
Zhang S; Li L; Shen A; Chen Y; Qi Z
Clin Drug Investig; 2020 Jun; 40(6):511-518. PubMed ID: 32337664
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
Michot JM; Albiges L; Chaput N; Saada V; Pommeret F; Griscelli F; Balleyguier C; Besse B; Marabelle A; Netzer F; Merad M; Robert C; Barlesi F; Gachot B; Stoclin A
Ann Oncol; 2020 Jul; 31(7):961-964. PubMed ID: 32247642
[No Abstract] [Full Text] [Related]
12. [First case of COVID-19 treated with tocilizumab in Iceland].
Bjornsson AH; Olafsdottir T; Thormar KM; Kristjansson M; Thorisdottir AS; Ludviksson BR; Guðmundsson S; Gottfredsson M
Laeknabladid; 2020 Mai; 106(5):247-250. PubMed ID: 32367812
[TBL] [Abstract][Full Text] [Related]
13. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
14. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
[No Abstract] [Full Text] [Related]
15. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
[TBL] [Abstract][Full Text] [Related]
16. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.
Masiá M; Fernández-González M; Padilla S; Ortega P; García JA; Agulló V; García-Abellán J; Telenti G; Guillén L; Gutiérrez F
EBioMedicine; 2020 Oct; 60():102999. PubMed ID: 32950003
[TBL] [Abstract][Full Text] [Related]
17. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T
Nephron; 2020; 144(9):459-462. PubMed ID: 32694244
[TBL] [Abstract][Full Text] [Related]
18. Cytokine release syndrome in severe COVID-19.
Moore JB; June CH
Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
[No Abstract] [Full Text] [Related]
19. Early tocilizumab treatment could improve survival among COVID-19 patients.
Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
[No Abstract] [Full Text] [Related]
20. Imatinib for COVID-19: A case report.
Morales-Ortega A; Bernal-Bello D; Llarena-Barroso C; Frutos-Pérez B; Duarte-Millán MÁ; García de Viedma-García V; Farfán-Sedano AI; Canalejo-Castrillero E; Ruiz-Giardín JM; Ruiz-Ruiz J; San Martín-López JV
Clin Immunol; 2020 Sep; 218():108518. PubMed ID: 32599278
[No Abstract] [Full Text] [Related]
[Next] [New Search]